The FDA has ordered a nationwide Rohto eye drops recall covering 12,460,649 bottles after saying it could not assure the products were sterile. The action reaches several Rohto Cooling Eye Drops brands sold individually and in two-packs, putting a large share of over-the-counter eye drop sales under immediate scrutiny.
The recall matters now because the FDA labeled it Class II, meaning the products may cause temporary, reversible effects and serious health consequences are unlikely. That judgment does not soften the order itself: consumers are being told not to use the recalled drops, to dispose of them or return them to the place where they were bought, and to contact a healthcare provider if symptoms appear after use.
Included in the recall are Rohto Cooling Eye Drops All-in-One, Rohto Cooling Eye Drops Max Strength, Rohto Cooling Eye Drops Optic Glow, Rohto Cooling Eye Drops Digi Eye, Rohto Cooling Eye Drops Dry Aid, Rohto Cooling Drops and Rohto Cooling Eye Drops Cool Relief. The FDA’s notice spans multiple product variants, and the scale alone — more than 12.4 million bottles — shows this is not a narrow lot-specific cleanup but a broad safety action across a national retail supply.
What the notice does not explain is the exact manufacturing or quality failure that left sterility in doubt. That absence matters because sterile eye products are expected to meet a basic safety standard before they ever reach a shelf, and once that standard cannot be guaranteed, the FDA has little room to treat the risk as theoretical.
For buyers, the next step is simple and immediate: stop using the products and get them out of circulation. The unresolved question is not whether the recall is real — it is — but which specific breakdown led the FDA to pull millions of bottles at once and whether any other Rohto eye drop products may face the same review.
